Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours

被引：0
|
作者：
Faidon-Marios Laskaratos
Martin Walker
Keval Naik
Emmanouil Maragkoudakis
Nikolaos Oikonomopoulos
Lee Grant
Tim Meyer
Martyn Caplin
Christos Toumpanakis
机构：
[1] Centre for Gastroenterology,Department of Infectious Disease Epidemiology
[2] Neuroendocrine Tumour Unit,Department of Radiology
[3] Centre for Gastroenterology,undefined
[4] Royal Free Hospital NHS Foundation Trust,undefined
[5] School of Public Health,undefined
[6] Faculty of Medicine,undefined
[7] Imperial College London,undefined
[8] Royal Free Hospital NHS Foundation Trust,undefined
[9] UCL Cancer Institute,undefined
[10] University College London,undefined
来源：
British Journal of Cancer | 2016年 / 115卷
关键词：
octreotide LAR; neuroendocrine tumours; antiproliferative activity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1321 / 1327
页数：6
相关论文
共 50 条
  • [31] First-line therapy in advanced renal cell carcinoma
    Rexer, H.
    Steiner, Th.
    Grunwald, V.
    UROLOGE, 2017, 56 (04): : 509 - 511
  • [32] Toxicity of high-activity 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours
    Caplin, ME
    Mielcarek, W
    Buscombe, JR
    Jones, AL
    Croasdale, PL
    Cooper, MS
    Burroughs, AK
    Hilson, AJW
    NUCLEAR MEDICINE COMMUNICATIONS, 2000, 21 (01) : 97 - 102
  • [33] Impact of Prior Somatostatin Analog (SSA) Use on PFS in the Multicenter, Phase III Trial of Everolimus plus Octreotide LAR Vs Placebo plus Octreotide LAR in Patients With Advanced Neuroendocrine Tumours (RADIANT-2)
    Pavel, M.
    Singh, N.
    Passos, V.
    Oberg, K.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S462 - S463
  • [34] Everolimus in combination with Octreotide LAR in first line setting for patients with neuroendocrine tumors (ITMO study): A 5-years update
    Bajetta, Emilio
    Catena, Laura
    Pusceddu, Sara
    Fazio, Nicola
    Sarno, Italo
    Di Menna, Giandomenico
    Dottorini, Lorenzo
    Marte, Anna Maria
    Turco, Carmela
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial
    Colao, A
    Pivonello, R
    Rosato, F
    Tita, P
    Menis, E
    Barreca, A
    Ferrara, R
    Mainini, F
    Arosio, M
    Lombardi, G
    CLINICAL ENDOCRINOLOGY, 2006, 64 (03) : 342 - 351
  • [36] Future options for first-line therapy of advanced ovarian cancer
    Du Bois, A
    Pfisterer, J
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 : 42 - 50
  • [37] First-Line Therapy in locally advanced or metastatic Urothelial Cancer
    Rexer, H.
    ONKOLOGE, 2012, 18 (01): : 70 - 71
  • [38] First-line Therapy of advanced or metastasized Renal cell cancer
    Rexer, H.
    UROLOGE, 2012, 51 (05): : 724 - 726
  • [39] Gencitabine and carboplatin as first-line therapy in advanced/metastatic NSCLC
    Savio, G.
    Laudani, A.
    Usset, A.
    Leonardi, V.
    Pepe, A.
    Palmisano, V.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2005, 16 : 24 - 25
  • [40] First-Line Therapy in locally advanced or metastatic Urothelial Cancer
    Rexer, H.
    ONKOLOGE, 2011, 17 (07): : 638 - 639
12345